---
title: Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive
  HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors
date: '2023-12-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38130467/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231222170724&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSION: Baseline and on-treatment modifications of peripheral blood
  lymphocytes have independent prognostic value in HR+/HER2- aBC patients. This study
  supports the implementation of clinical strategies to boost antitumor immunity in
  patients with HR+/HER2- aBC treated with ETs plus ...'
disable_comments: true
---
CONCLUSION: Baseline and on-treatment modifications of peripheral blood lymphocytes have independent prognostic value in HR+/HER2- aBC patients. This study supports the implementation of clinical strategies to boost antitumor immunity in patients with HR+/HER2- aBC treated with ETs plus ...